Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 1
1999 1
2001 1
2003 1
2005 1
2007 2
2008 4
2009 2
2010 1
2011 4
2012 3
2013 1
2014 3
2015 2
2016 3
2017 2
2018 3
2019 5
2020 2
2021 4
2022 3
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Sims JR, et al. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239. JAMA. 2023. PMID: 37459141 Free PMC article.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Validation of the German Montreal-Cognitive-Assessment-H for hearing-impaired.
Völter C, Fricke H, Faour S, Lueg G, Nasreddine ZS, Götze L, Dawes P. Völter C, et al. Among authors: nasreddine zs. Front Aging Neurosci. 2023 Jul 19;15:1209385. doi: 10.3389/fnagi.2023.1209385. eCollection 2023. Front Aging Neurosci. 2023. PMID: 37539344 Free PMC article.
Brief screening tool for mild cognitive impairment in older Japanese: validation of the Japanese version of the Montreal Cognitive Assessment.
Fujiwara Y, Suzuki H, Yasunaga M, Sugiyama M, Ijuin M, Sakuma N, Inagaki H, Iwasa H, Ura C, Yatomi N, Ishii K, Tokumaru AM, Homma A, Nasreddine Z, Shinkai S. Fujiwara Y, et al. Among authors: nasreddine z. Geriatr Gerontol Int. 2010 Jul;10(3):225-32. doi: 10.1111/j.1447-0594.2010.00585.x. Epub 2010 Feb 4. Geriatr Gerontol Int. 2010. PMID: 20141536
Multicenter Validation of an MMSE-MoCA Conversion Table.
Bergeron D, Flynn K, Verret L, Poulin S, Bouchard RW, Bocti C, Fülöp T, Lacombe G, Gauthier S, Nasreddine Z, Laforce RJ. Bergeron D, et al. Among authors: nasreddine z. J Am Geriatr Soc. 2017 May;65(5):1067-1072. doi: 10.1111/jgs.14779. Epub 2017 Feb 15. J Am Geriatr Soc. 2017. PMID: 28205215
50 results